Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Maladjustment Of Programmable Ventricular Shunt Valves By Inadvertent Exposure To A Common Hospital Device, R. Fujimura, Robert M. Lober, K. Kamian, L. Kleiner
Maladjustment Of Programmable Ventricular Shunt Valves By Inadvertent Exposure To A Common Hospital Device, R. Fujimura, Robert M. Lober, K. Kamian, L. Kleiner
Pediatrics Faculty Publications
Background: Programmable ventricular shunt valves are commonly used to treat hydrocephalus. They can be adjusted to allow for varying amounts of cerebrospinal fluid (CSF) flow using an external magnetic programming device, and are susceptible to maladjustment from inadvertent exposure to magnetic fields.Case Description: We describe the case of a 3‑month‑old girl treated for hydrocephalus with a programmable StrataTM II valve found at the incorrect setting on multiple occasions during her hospitalization despite frequent reprogramming and surveillance. We found that the Vocera badge, a common hands‑free wireless communication system worn by our nursing staff, had a strong enough magnetic field to …
Preclinical Pharmacokinetic Evaluation To Facilitate Repurposing Of Tyrosine Kinase Inhibitors Nilotinib And Imatinib As Antiviral Agents, Hari Krishna Ananthula, Scott Parker, Erin Touchette, R. Mark Buller, Gopi Patel, Daniel Kalman, Johanna S. Salzer, Nadia Gallardo-Romero, Victoria Olson, Inger K. Damon, Tessa Moir-Savitz, Larry Sallans, Milton H. Werner, Catherine M.T. Sherwin, Pankaj B. Dasai
Preclinical Pharmacokinetic Evaluation To Facilitate Repurposing Of Tyrosine Kinase Inhibitors Nilotinib And Imatinib As Antiviral Agents, Hari Krishna Ananthula, Scott Parker, Erin Touchette, R. Mark Buller, Gopi Patel, Daniel Kalman, Johanna S. Salzer, Nadia Gallardo-Romero, Victoria Olson, Inger K. Damon, Tessa Moir-Savitz, Larry Sallans, Milton H. Werner, Catherine M.T. Sherwin, Pankaj B. Dasai
Pediatrics Faculty Publications
Background
Several tyrosine kinase inhibitors (TKIs) developed as anti-cancer drugs, also have anti-viral activity due to their ability to disrupt productive replication and dissemination in infected cells. Consequently, such drugs are attractive candidates for “repurposing” as anti-viral agents. However, clinical evaluation of therapeutics against infectious agents associated with high mortality, but low or infrequent incidence, is often unfeasible. The United States Food and Drug Administration formulated the “Animal Rule” to facilitate use of validated animal models for conducting anti-viral efficacy studies.
Methods
To enable such efficacy studies of two clinically approved TKIs, nilotinib, and imatinib, we first conducted comprehensive pharmacokinetic …